Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analysts have given Prestige Consumer Healthcare Inc. a consensus rating of "Hold", with one sell rating, three holds, and three buy ratings among seven brokerages.
• The company's latest earnings report showed a net margin of 19.02% and revenue of $249.53 million, falling short of the consensus estimate of $260.71 million.
• Institutional investors currently own 99.95% of Prestige Consumer Healthcare, with Bank of America Corp DE increasing its holdings by 6.4% during the last quarter.

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have been given an average recommendation of "Hold" by the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $93.3333.

Several research firms have recently commented on PBH. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Zacks Research lowered shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday, September 4th.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded down $1.09 during midday trading on Wednesday, hitting $62.16. The company's stock had a trading volume of 84,573 shares, compared to its average volume of 407,542. Prestige Consumer Healthcare has a 1-year low of $62.71 and a 1-year high of $90.04. The firm's fifty day moving average price is $70.53 and its 200-day moving average price is $79.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The firm has a market cap of $3.06 billion, a P/E ratio of 14.56, a P/E/G ratio of 2.00 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same period last year, the firm posted $0.90 earnings per share. The company's quarterly revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company's stock valued at $26,000 after purchasing an additional 144 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 312.5% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock valued at $26,000 after purchasing an additional 250 shares during the period. Maseco LLP acquired a new position in Prestige Consumer Healthcare during the 2nd quarter valued at about $27,000. Opal Wealth Advisors LLC acquired a new position in Prestige Consumer Healthcare during the 1st quarter valued at about $38,000. Finally, Geneos Wealth Management Inc. boosted its stake in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.